Glucocorticoids delay RAF-induced senescence promoted by EGR1

Area of Science:

• Cellular senescence
• Oncogene-induced proliferation
• Molecular signaling pathways

Background:

• Hyperactive RAF kinases, like B-RAF-V600E, trigger cellular senescence, a state of irreversible growth arrest that prevents tumor formation.
• Glucocorticoids are potent regulators of cellular processes, including stress responses and inflammation, with known roles in cell proliferation and survival.

Purpose of the Study:

• To investigate the effect of glucocorticoids on oncogene-induced senescence (OIS) triggered by B-RAF-V600E.
• To elucidate the molecular mechanisms by which glucocorticoids influence senescence entry and bypass.

Main Methods:

• Human fibroblasts expressing B-RAF-V600E were treated with glucocorticoids.
• Senescence entry and bypass were assessed through cell proliferation assays and regular passaging.
• Transcriptome and siRNA analyses were performed to identify molecular targets of glucocorticoid action.
• Expression levels of EGR1, p15, and p21 were quantified.

Main Results:

• Glucocorticoids delayed the onset of senescence induced by B-RAF-V600E in human fibroblasts.
• Regular passaging of glucocorticoid-treated cells allowed for senescence bypass, but did not affect cells already in senescence.
• Glucocorticoids were found to target the EGR1 gene, which is regulated by the RAF-MEK-ERK MAPK pathway.
• EGR1 regulates p15 and p21, which are crucial for the proliferative arrest observed in BJ fibroblasts expressing B-RAF-V600E.

Conclusions:

• Glucocorticoids can modulate the response to oncogenic B-RAF-V600E by delaying senescence.
• The EGR1 gene and its downstream targets p15 and p21 are key mediators of glucocorticoid action in OIS.
• These findings suggest that glucocorticoid's impact on senescence evasion warrants further investigation in cancers driven by B-RAF-V600E, such as melanoma, thyroid, and colon carcinomas.